VITASPRING BIOMEDICAL CO., LTD. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
VITASPRING BIOMEDICAL CO., LTD. (VSBC) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 32.97 million shares for the 12-month period ending 2025-01-31, per its 10-K filed 2026-06-08.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2026-06-08
- VITASPRING BIOMEDICAL CO., LTD. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2025-01-31 was 0.00 shares.
- VITASPRING BIOMEDICAL CO., LTD. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2024-10-31 was 32.97M shares.
- VITASPRING BIOMEDICAL CO., LTD. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2024-07-31 was 0.00 shares.
- VITASPRING BIOMEDICAL CO., LTD. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2024-04-30 was 0.00 shares.
- VITASPRING BIOMEDICAL CO., LTD. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2025 was 32.97M shares, a 0.00% change from fiscal 2024.
- VITASPRING BIOMEDICAL CO., LTD. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2024 was 32.97M shares, a 0.00% change from fiscal 2023.
- VITASPRING BIOMEDICAL CO., LTD. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2023 was 32.97M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month |
|---|---|---|---|---|
| 2025-01-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-08 | 32.97M shares derived: sum of 2 quarters · filed 2026-06-08 | 32.97M shares derived: sum of 3 quarters · filed 2026-06-08 | 32.97M shares 10-K · filed 2026-06-08 |
| 2024-10-31 | 32.97M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-06 | 32.97M shares derived: sum of 2 quarters · filed 2026-05-06 | 32.97M shares 10-Q · filed 2026-05-06 | 32.97M shares derived: sum of 4 quarters · filed 2026-06-08 |
| 2024-07-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-04-22 | 0.00 shares 10-Q · filed 2026-04-22 | 0.00 shares derived: sum of 3 quarters · filed 2026-06-08 | |
| 2024-04-30 | 0.00 shares 10-Q · filed 2026-04-02 | 0.00 shares derived: sum of 2 quarters · filed 2026-06-08 | ||
| 2024-01-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-08 | 32.97M shares 10-K · filed 2026-06-08 | ||
| 2023-10-31 | 32.97M shares 10-Q · filed 2026-01-30 | |||
| 2023-01-31 | 32.97M shares 10-K · filed 2026-03-12 |